Remdesivir ke setlhare sa antiviral se lebisang ho mefuta e mengata ea livaerase. E qalile lilemong tse leshome tse fetileng ho phekola lefu la sebete la C le kokoana-hloko e kang sefuba e bitsoang "respiratory syncytial virus" (RSV). Remdesivir e ne e se pheko e sebetsang bakeng sa lefu lena ka bobeli. Empa e ne e bontša tšepiso khahlanong le likokoana-hloko tse ling.

Bafuputsi ba ile ba etsa liteko tsa remdesivir litekong tsa bongaka nakong ea koluoa ​​​​ea Ebola. Meriana e meng ea lipatlisiso e ne e sebetsa betere, empa ho ile ha bontšoa hore e bolokehile ho bakuli. Boithuto ka liseleng le liphoofolong bo khothalelitse hore remdesivir e sebetsa khahlano le livaerase tsa lelapa la coronavirus, joalo ka Middle East Respiratory Syndrome (MERS) le Severe Acute Respiratory Syndrome (SARS).

Remdesivir e sebetsa ka ho sitisa tlhahiso ea vaerase. Li-Coronavirus li na le liphatsa tsa lefutso tse entsoeng ka ribonucleic acid (RNA). Remdesivir e kena-kenana le e 'ngoe ea li-enzyme tsa bohlokoa tseo vaerase e li hlokang ho etsa RNA. Sena se thibela kokoana-hloko ho ikatisa.

Bafuputsi ba ile ba qala teko e sa reroang, e laoloang ea antiviral ka Hlakola 2020 ho leka hore na remdesivir e ka sebelisoa ho phekola SARS-CoV-2, coronavirus e bakang COVID-19. Ka April,liphetho tsa pelee bontšitse hore remdesivir e potlakisitse ho fola ho bakuli ba sepetlele ba nang le COVID-19 e matla. E bile setlhare sa pele ho fumana tumello ea ts'ebeliso ea tšohanyetso ho tsoa ho US Food and Drug Administration (FDA) ho phekola batho ba sepetlele ka COVID-19.

Hona joale bafuputsi ba qetile teko, e tsejoang ka hore ke Adaptive COVID-19 Treatment Trial (ACTT-1). Boithuto bona bo tšehelitsoe ka lichelete ke Setsi sa Naha sa Allergy le Mafu a tšoaetsanoang (NIAID). Tlaleho ea ho qetela e hlahile hoNew England Journal of Medicineka la 8 Mphalane 2020.